Related Experiment Videos

The effect of tumor burden on ornithine decarboxylase activity in mice

R Saydjari1, R W Alexander, J R Upp

  • 1Department of Surgery, University of Texas Medical Branch, Galveston 77550.

Cancer Investigation
|January 11, 1991
PubMed

Insights

The study found that the presence of a tumor alters ornithine decarboxylase (ODC) activity in mice. Alpha-difluoromethylornithine (DFMO) effectively reduced ODC in tumors but not in other organs, suggesting systemic effects of the tumor.

Area of Science:

  • Biochemistry
  • Oncology
  • Pharmacology

Background:

  • Polyamines are crucial for cell proliferation in both normal and cancerous tissues.
  • Alpha-difluoromethylornithine (DFMO) is a potent inhibitor of ornithine decarboxylase (ODC), a key enzyme in polyamine synthesis.

Purpose of the Study:

  • To investigate how tumor burden influences ODC activity in various tissues.
  • To assess the impact of DFMO on ODC activity in tumor-bearing versus tumor-free mice.

Main Methods:

  • MC-26 colon adenocarcinoma cells were used to establish tumors in Balb/c mice.
  • Mice were divided into tumor-bearing and tumor-free groups, with some receiving DFMO and others saline.
  • ODC activity was measured in excised tumors, pancreas, kidney, and liver post-treatment.

Main Results:

  • DFMO significantly reduced ODC activity in tumors compared to controls.
  • Tumor-bearing mice exhibited lower basal ODC activity in the kidney, liver, and pancreas than tumor-free mice.
  • DFMO administration did not affect ODC activity in the kidney, pancreas, or liver of tumor-bearing mice, but lowered it in tumor-free mice.

Conclusions:

  • The presence of MC-26 tumors induces systemic changes affecting ODC activity.
  • Tumor burden modifies the response of ODC to DFMO inhibition.
  • These findings highlight complex interactions between tumors and host metabolism.

Related Concept Videos